spacer
home > ict > autumn 2017 > fastening pharmaceuticals
PUBLICATIONS
International Clinical Trials

Fastening Pharmaceuticals

As consumers increasingly embrace the more affordable nature of wearable devices choosing to monitor their own health and wellbeing with gadgets such as FitBit or Jawbone it is no surprise that the wearable device market is set to grow to 25 billion by 2019 (1). However, this wearable technology has also been widely adopted by other markets, and none more so than by the healthcare industry, which reportedly earned revenues of $5.1 billion in 2015, according to a recent report by Frost and Sullivan (2). This wearable devices market is set to continue to revolutionise the healthcare industry with estimates that it will reach over $18 billion by 2020 (3).

It has been widely reported that CROs can leverage this wearable device trend to enable easier remote patient monitoring, improved therapeutic outcomes and deeper insight into clinical studies. Alongside this, traditional outsourcing in the area of clinical trial data management is seeing notable increases in market concentration, while speciality service providers are experiencing unprecedented growth. The Tufts Center for the Study of Drug Development estimates that, since 2011, small niche or speciality service providers have enjoyed strong relative annual growth, approaching 10% (4).

However, the clinical trial process is known to be complex, painstaking and is often criticised for not being sufficiently patient-centric. Therefore, it makes sense to innovate in this area to ease the challenges, streamline the various activities and generate better patient engagement. One way to do this is via digital technology and mobile health (5).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jeremy Wheeler, Head of Statistics at Quanticate, is an experienced statistician with over 25 years' experience, including over 10 years in the pharma industry. He has worked in all phases of drug development, with particular knowledge of clinical studies, early phase design and analysis, methodology/biomarker studies and pharmacogenomics. Jeremy has a strong background in epidemiology and observational studies. He has applied this knowledge to post-marketing studies, meta-analyses and clinical registry studies.
spacer
Jeremy Wheeler
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.
More info >>

White Papers

Preparation of Pharmaceutical Samples for Metals Analysis

RSSL

There has been a lot of discussion regarding the methods of analysis for pharmaceutical products as we await the upcoming changes to both the EP and USP, relating to the analysis of metal impurities.
More info >>

 
Industry Events

10th Annual NGS & Clinical Diagnostics Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 10thAnnual NGS & Clinical Diagnostics Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement